NewsMeter

Apimeds locks in 25% Apitox royalty and full Korean clinic rights in FreeT assignment

8/24/2026

Twenty-five percent is the royalty entitlement on U.S. Apitox economic proceeds that Apimeds Pharmaceuticals US, Inc.

(APUS) has now pulled onto its own books, matching the 25% revenue participation right it simultaneously acquired on net proceeds from overseas rights agreements.

Together with a 100% stake in Apitox rights for Korean medicine clinics in the Republic of Korea, those streams form the complete block of Assigned Rights that FreeT Inc.

irrevocably transferred to Apimeds on August 19, 2026, under an Assignment and Transfer Agreement filed that day with the SEC.